OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Townsend on the Genetic Evolutionary Trajectory of Prostate Cancer

April 24th 2024

Jeffrey P. Townsend, PhD, on a novel approach to comprehending the evolutionary trajectory of prostate cancer through genetic profiling.

Dr Baretti on Entinostat Plus Nivolumab in Advanced PDAC

April 24th 2024

Marina Baretti, MD, on results from a phase 2 study of entinostat in combination with nivolumab for the treatment of advanced pancreatic ductal adenocarcinoma.

Dr Simon on the ALK Inhibitor Selection Process in ALK+ NSCLC

April 24th 2024

George R Simon, MD, FACP, FCCP on selecting ALK inhibitors in ALK-positive non–small cell lung cancer.

Dr Usmani on the Design of the CARTITUDE-4 Trial in Multiple Myeloma

April 24th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.

Dr Kristeleit on the Implications of Long-Term Data With Rucaparib in Advanced Ovarian Cancer

April 23rd 2024

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Dr Dizon on the Future of Precision Medicine in Ovarian Cancer Management

April 23rd 2024

Don S. Dizon, MD, FACP, FASCO, discusses future directions for precision medicine approaches in ovarian cancer.

Dr Garje on the Use of Genomic Testing and Targeted Therapy in Prostate Cancer

April 23rd 2024

Rohan Garje, MD, discusses the evolving use of genomic testing and targeted treatment approaches in prostate cancer.

Dr Leary on the FDA Approval of Tovorafenib for Pediatric R/R BRAF+ Low-Grade Glioma

April 23rd 2024

Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.

Dr Srour on the Ongoing Investigation of CAR T-Cell Therapy in Advanced RCC

April 23rd 2024

Samer A. Srour, MB ChB, MS, discusses the investigation of the allogeneic CAR T-cell therapy CTX131 in advanced clear cell renal cell carcinoma.

Dr Nanda on the Evolution of Treatment For HER2-Low Breast Cancer

April 23rd 2024

Rita Nanda, MD, discusses the evolution of treatment options for patients with HER2-low breast cancer.

Dr Narayan on the Mechanism of Action of Nadofaragene Firadenovec in NMIBC

April 23rd 2024

Vikram Narayan, MD, discusses the mechanism of action of nadofaragene firadenovec in patients with high-risk non–muscle invasive bladder cancer.

Dr Olson on the Potential Benefit of Lifileucel in Relapsed/Refractory Metastatic Melanoma

April 23rd 2024

Daniel Olson, MD, discusses the benefit associated with lifileucel in patients with unresectable or metastatic melanoma.

Dr Patel on the Evolving Use of Neoadjuvant PD-1 Inhibitors in CSCC

April 22nd 2024

Vishal Patel, MD, FAAD, FACMS, discusses the evolving use of neoadjuvant and adjuvant PD-1 inhibition in cutaneous squamous cell carcinoma.

Dr Coombs on the Ongoing Investigation of Quizartinib in AML

April 22nd 2024

Catherine C. Coombs, MD, discusses the efficacy of the FLT3 inhibitor quizartinib in acute myeloid leukemia.

Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia

April 19th 2024

Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.

Dr Lenz on the Prognostic Value of HER2 Expression in mCRC

April 19th 2024

Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.

Dr Jagannath on the Mechanism of Action of Linvoseltamab in R/R Multiple Myeloma

April 19th 2024

Sundar Jagannath, MBBS, discusses the mechanism of action and tolerability of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Hamid on Addressing Unmet Needs in Relapsed Melanoma With Lifileucel

April 19th 2024

Omid Hamid, MD, discusses how lifileucel may address historical unmet needs in relapsed melanoma.

Dr Roland on a Study of Neoadjuvant Immune-Checkpoint Blockade Across Sarcoma Subtypes

April 19th 2024

Christina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.

Dr Saxena on Shifts in Treatment With Targeted and Immune Therapies in NSCLC

April 19th 2024

Ashish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.